Salspera Technologies

Salspera Technologies is a clinical-stage biotechnology company focused on developing novel microbial-based immunotherapies for the treatment of difficult-to-treat solid tumors. The company's proprietary Saltikva platform utilizes an attenuated strain of Salmonella typhimurium designed to colonize tumors and deliver therapeutic payloads, such as Interleukin-2, directly into the tumor microenvironment. This approach aims to stimulate a potent immune response while minimizing systemic toxicity typically associated with systemic cytokine administration. Salspera's lead program, SALS-P901, is currently being evaluated in Phase 2 clinical trials for patients with metastatic pancreatic cancer. By leveraging the natural tumor-homing abilities of bacteria, the company seeks to transform the treatment landscape for cancers that are traditionally resistant to conventional immunotherapies.